Search results
Added:
2 years ago
Dr Giulio Stefanini (Humanitas Research Hospital, Milan, IT) discusses the findings from the multicentre POEM trial.The trial assessed the safety of the bioresorbable polymer-coated everolimus-eluting Synergy® stent in CAD patients undergoing PCI, followed by 1-month dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR).
Questions:
1. What is the POEM Study and what does it…
View more
Vijay U Rao
Research Area(s) / Expertise:
Job title: Director Heart Failure, Cardio-oncology and Co-Director Anticoagulation at Franciscan St Francis Health
Author
Added:
6 years ago
This interview with Christopher P. Cannon from Brigham and Women's Hospital, Boston, US discusses Dual Antithrombotic Therapy with Dabigatran After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation (REDUAL-PCI).
Filmed by Radcliffe Cardiology on-site at ESC 2017.
View more
Added:
2 years ago
In this short interview, Dr Duk-Woo Park (Asan Medical Center, KR) discusses the findings from the ADAPT-TAVR Randomized Clinical Trial (NCT03284827).
The trial investigated Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR.
Presented first at ACC.22, ADAPT-TAVR shows that the overall incidence of leaflet thrombosis on CT scans was less…
View more
Added:
3 years ago
Atrial fibrillation (AF) is the most frequent sustained arrhythmia. The estimation is that five million people suffer the disease in Europe,1 although this number may be even higher because many AF episodes are silent but still associated with a risk of complications.2–4 AF prevalence is increasing in developed countries in part due to the progressive increase in the mean age of the western…
View more
Added:
1 year ago
What are the take-home messages from ESC 22 and what are the implications for practice?
In this short wrap-up video of ESC 22, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) review the most impactful hot line and late-breaking trials of ESC Congress 2022.
Trials covered in detail include:
On clinical judgement after PCI
00:35:27:REVIVED-BCIS2: Study of…
View more
Robert F Storey
Job title: Professor and Honorary Consultant in Cardiology
Author
Added:
1 year ago
ESC Congress 22 — Dr Sanjit Jolly (Population Health Research Institute, CA) talk about the Anti-Coronavirus Therapies (ACT) trials (NCT04324463).
The data is from two parallel trials assessing the effects of interventions in inpatients and outpatients with COVID-19.
The ACT trials are testing whether anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin in…
View more
Added:
1 year ago
In this short and engaging episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most impactful hot-line and late-breaking trials from ESC 2022.
Which trials should we look out for?
Trials covered in detail include:
TAILOR-PCI: Tailored Antiplatelet Therapy Following PCI
ASCEND: A Study of…
View more
Added:
3 years ago
Abstract
After the release of the 2010 guidelines of the European Society of Cardiology (ESC) and the 2011 update of the guidelines of the American Heart Association/American College of Cardiology (AHA/ACC), new evidence has emerged that requires adaption of current clinical practice in the treatment of atrial fibrillation (AF). In 2011, results were published from two central AF trials…
View more
« First